SCHEMBL7128679

SCHEMBL7128679

Nc1nc(Sc2ccccc2)c2ncn(CCOCP(CC(F)(F)F)CC(F)(F)F)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.41
CYP2C19 P33261 4/20 0.41
CYP2C9 P11712 3/20 0.41
HIF1A Q16665 3/20 0.41
CYP3A4 P08684 2/20 0.41
ALDH1A1 P00352 1/20 0.41
PHLPP2 Q6ZVD8 1/20 0.41
SLC29A1 Q99808 3/20 0.40
CYP2D6 P10635 2/20 0.37
ADORA2A P29274 2/20 0.35
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
HK1 P19367 1/20 0.34
HKDC1 Q2TB90 1/20 0.34
MGMT P16455 1/20 0.34
HRH4 Q9H3N8 1/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7769163 0.93 CYP1A2 (0.37) CYP1A2CYP2C19CYP2C9HIF1ACYP3A4
SCHEMBL7119645 0.92 CYP2C19 (0.38) CYP1A2CYP2C19CYP2C9HIF1ACYP3A4
SCHEMBL7759477 0.91 CYP2C19 (0.38) CYP1A2CYP2C19CYP2C9HIF1ACYP3A4
SCHEMBL7765786 0.91 CYP1A2 (0.46) CYP1A2CYP2C19CYP2C9HIF1ACYP3A4
SCHEMBL7116907 0.89 CYP2C19 (0.35) CYP1A2CYP2C19CYP2C9HIF1ACYP3A4
SCHEMBL7769155 0.89 DHFR (0.42) CYP1A2CYP2C19CYP2C9HIF1ACYP3A4
SCHEMBL6837777 0.89 NSD3 (0.40) CYP1A2CYP2C19CYP2C9HIF1ACYP3A4
Hydrochloric Acid SCHEMBL7765789 0.88 NSD3 (0.39) CYP1A2CYP2C19CYP2C9HIF1ACYP3A4
SCHEMBL7118711 0.88 CYP1A2 (0.38) CYP1A2CYP2C19CYP2C9HIF1ACYP3A4
SCHEMBL7126789 0.88 DHFR (0.42) CYP1A2CYP2C19CYP2C9HIF1ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030109498-A1 Antiviral agent for drug-resistant virus MITSUBISHI PHARMA CORPORATION (JP) 2003-06-12 US claimed
EP-0785208-B1 Phosphonate nucleotide compounds MITSUBISHI CHEM CORP (JP) 2001-03-21 EP claimed
EP-0785208-A1 Phosphonate nucleotide compounds MITSUBISHI CHEMICAL CORPORATION (JP) 1997-07-23 EP claimed
EP-2846788-A1 USE OF COMPOUNDS FOR THE TREATMENT OF PAIN Akron Molecules AG (AT) 2015-03-18 EP disclosed
WO-2013167743-A1 USE OF COMPOUNDS FOR THE TREATMENT OF PAIN AKRON MOLECULES GMBH (AT) 2013-11-14 WO disclosed
US-20030109498-A1 Antiviral agent for drug-resistant virus MITSUBISHI PHARMA CORPORATION (JP) 2003-06-12 US disclosed
EP-0785208-B1 Phosphonate nucleotide compounds MITSUBISHI CHEM CORP (JP) 2001-03-21 EP disclosed
EP-0785208-A1 Phosphonate nucleotide compounds MITSUBISHI CHEMICAL CORPORATION (JP) 1997-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109498-A1 Antiviral agent for drug-resistant virus TPMT, MTAP, TYMP CYP1A2 1083/4885CYP2C19 787/4885CYP2C9 408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.